Aljian Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.67M Buy
1,811
+592
+49% +$600K 0.34% 41
2025
Q4
$1.31M Buy
1,219
+1
+0.1% +$956 0.26% 50
2025
Q3
$929K Sell
1,218
-1
-0.1% -$744 0.19% 61
2025
Q2
$950K Buy
1,219
+1
+0.1% +$777 0.21% 58
2025
Q1
$1.01M Buy
1,218
+3
+0.2% +$2.5K 0.24% 54
2024
Q4
$938K Sell
1,215
-14
-1% -$11.6K 0.2% 51
2024
Q3
$1.09M Buy
+1,229
New +$1.1M 0.25% 47

Other funds holding LLY

Aljian Capital Management's LLY Position: Q1 2026 in Review

Aljian Capital Management increased its Eli Lilly (LLY) stake by 49% in Q1 2026, buying an estimated $600K and bringing the position to 1,811 shares worth $1.67M. The position accounts for 0.34% of the portfolio, ranked #41.

Aljian Capital Management first reported a position in LLY in Q3 2024 and has held it in 7 quarters since. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Aljian Capital Management held 1,811 shares of Eli Lilly worth $1.67M as of Q1 2026.
  • Aljian Capital Management bought 592 Eli Lilly shares in Q1 2026, an estimated $600K.
  • Eli Lilly made up 0.34% of Aljian Capital Management's portfolio in Q1 2026, its #41 holding.
  • Aljian Capital Management first reported a position in Eli Lilly in Q3 2024 and has held it in 7 quarters since.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Aljian Capital Management's 13F filing for Q1 2026, filed 29 Apr 2026.